Tuberculosis screening of travelers to higher-incidence countries: A cost-effectiveness analysis

BMC Public Health

Volumn 8, Issue , 2008, Pages

  Tan, Michael ^a,b   Menzies, Dick ^a,b   Schwartzman, Kevin ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE SYSTEM; INFECTION RISK; MORBIDITY; SCREENING TEST; THORAX RADIOGRAPHY; TRAVEL; TUBERCULIN TEST; TUBERCULOSIS; ADULT; CANADA; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DOMINICAN REPUBLIC; ECONOMICS; EPIDEMIC; HAITI; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MASS SCREENING; MEXICO; PROBABILITY; SKIN TEST; STATISTICS; UNITED STATES;

ADULT; CANADA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE OUTBREAKS; DOMINICAN REPUBLIC; HAITI; HUMANS; INCIDENCE; MARKOV CHAINS; MASS CHEST X-RAY; MASS SCREENING; MEXICO; SKIN TESTS; TRAVEL; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 46749137513     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-8-201     Document Type: Article

References (57)

1. Reported Tuberculosis in the United States, 2004. Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, Division of Tuberculosis Elimination (DTBE) 2005 http://www.cdc.gov/tb/surv/surv2004/ default.htm Accessed January 14, 2008
2. Tuberculosis in Canada 2004 Pre-release. Public Health Agency of Canada E Ellis V Gallant Dx Scholten M Miron, Public Health Agency of Canada Publications: Tuberculosis Prevention and Control 2006 http://www.phac-aspc.gc. ca/publicat/tbcan-pre04/pdf/tbcan-pre_2004_e.pdf Accessed January 14, 2008
3. National survey of tuberculosis notifications in England and Wales 1978-9. Medical Research Council tuberculosis and Chest Diseases Unit, Br Med J 1980 281 895 898 7427500
4. Asian immigrant tuberculosis-the effect of visiting Asia. OR McCarthy, Br J Dis Chest 1984 78 3 248 253 10.1016/S0007-0971(84)80118-7 6743520
5. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. MN Lobato PC Hopewell, Am J Respir Crit Care Med 1998 158 6 1871 1875 9847280
6. Risk factors for latent tuberculosis infection among children in New York City. L Saiman GP San J Schulte MP Vargas T Kenyon I Onorato, Pediatrics 2001 107 5 999 1003 10.1542/peds.107.5.999 11331677
7. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. FG Cobelens DH Van IW Draayer-Jansen AC Schepp-Beelen PJ van Gerven RP van Kessel, Lancet 2000 356 9228 461 465 10.1016/S0140-6736(00)02554-X 10981889
8. Health Information for International Travel - The "Yellow Book": Chapter 4 - Prevention of Specific Infectious Diseases: Tuberculosis (2005-2006). Centers for Disease Control and Prevention, CDC Travelers' Health: Yellow Book http://wwwn.cdc.gov/travel/YellowBookCh4-TB.aspx Accessed January 14, 2008
9. The risk and prevention of tuberculosis in travelers. Public Health Agency of Canada, Committee to Advise on Tropical Medicine and Travel, Public Health Agency of Canada, Canada Communicable Disease Report 1997 23 ACS-5 http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/97vol23/23sup/acs5.html Accessed January 14, 2008
10. Domestic returns from investment in the control of tuberculosis in other countries. K Schwartzman O Oxlade RG Barr F Grimard I Acosta J Baez, N Engl J Med 2005 353 10 1008 1020 10.1056/NEJMsa043194 16148286
11. Cost-effectiveness in health and medicine. MR Gold JE Siegel LB Russell MC Weinstein eds, New York: Oxford University Press 1996
12. Global tuberculosis control surveillance, planning, financing WHO Report 2006. WHO, WHO, Programmes and Projects, Tuberculosis http://www.who.int/tb/ publications/global_report/2006/en/index.html Accessed January 14, 2008
13. The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. K Styblo, Bulletin of the International Union against Tuberculosis 1985 60 117 119
14. United States Life Tables 2002. Centers for Disease Control and Prevention, National Center for Health Statistics, CDC National Center for Health Statistics: National Vital Statistics Reports 53 6 http://www.cdc.gov/ nchs/data/dvs/life2002.pdf Accessed January 14, 2008
15. Duchesne D. Life tables, Canada, provinces and territories, 1995-1997. Statistics Canada, Statistics Canada, Summary Tables http://www.statcan.ca/ english/freepub/84-537-XIE/84-537-XIE1997001.htm Accessed January 14, 2008
16. WHO-UNICEF estimates of BCG coverage. World Health Organization, WHO, Immunization, surveillance, assessment & monitoring http://www.who.int/ immunization_monitoring/en/globalsummary/timeseries/tswucoveragebcg.htm Accessed January 14, 2008
17. Effect of Bacille Calmette-Guerin vaccination on tuberculin reactivity. RI Menzies B Vissandjee, Am Rev Respir Dis 1992 145 621 625 1546843
18. False positive tuberculin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria. M Farhat C Greenaway M Pai D Menzies, Int J Tuberc Lung Dis 2006 10 1192 1204 17131776
19. Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. EE Salpeter SR Salpeter, Am J Epidemiol 1998 147 398 406 9508108
20. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. MA Behr SA Warren H Salamon PC Hopewell LA Ponce de CL Daley, Lancet 1999 353 9151 444 449 10.1016/S0140-6736(98)03406-0 9989714
21. Tuberculosis diagnosed by active vs. passive case-finding. S Mubareka M Perrault I Rocher D Menzies K Schwartzman, Am J Respir Crit Care Med 2004 163 A100
22. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. K Schwartzman D Menzies, Am J Respir Crit Care Med 2000 161 780 789 10712322
23. Tuberculin screening: cost-effectiveness analysis of various testing schedules. CB Schechter DN Rose MC Fahs AL Silver, Am J Prev Med 1990 6 167 175 2118787
24. School-based screening for tuberculous infection. A cost-benefit analysis. JC Mohle-Boetani B Miller M Halpern A Trivedi J Lessler SL Solomon, JAMA 1995 274 8 613 619 10.1001/jama.274.8.613 7637141
25. Medicare Payment Systems and Coding Files. US Department of Health and Human Services, HHS, Centers for Medicare & Medicaid Services http://www.cms.hhs.gov/home/medicare.asp Accessed January 14 2008
26. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. K Dasgupta K Schwartzman R Marchand TN Tennenbaum P Brassard D Menzies, Am J Respir Crit Care Med 2000 162 6 2079 2086 11112118
27. Consumer Price Index Inflation Calculator. U S Bureau of Labor Statistics, http://data.bls.gov/cgi-bin/cpicalc.pl Accessed January 14, 2008
28. Inflation Calculator. Bank of Canada, Rates and Statistics, http://www.bankofcanada.ca/en/rates/inflation_calc.html Accessed January 14, 2008
29. Feasibility and reliability of health-related quality of life measurements among tuberculosis patients. MJ Dion P Tousignant J Bourbeau D Menzies K Schwartzman, Qual Life Res 2004 13 3 653 665 10.1023/B:QURE. 0000021320.89524.64 15130028
30. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. G Ferrara M Losi R D'Amico P Roversi R Piro M Meacci, Lancet 2006 367 9519 1328 1334 10.1016/S0140-6736(06)68579-6 16631911
31. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. M Pai LW Riley JM Colford Jr, Lancet Infect Dis 2004 4 12 761 776 10.1016/S1473-3099(04)01206-X 15567126
32. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. O Oxlade K Schwartzman D Menzies, Int J Tuberc Lung Dis 2007 11 16 26 17217125
33. Controlled chemoprophylaxis trials in tuberculosis. SH Ferebee, Adv Tuberc Res 1969 17 28 106
34. Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study. CM Nolan AM Elarth, Am Rev Respir Dis 1988 137 4 805 809 3354985
35. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? GW Comstock, Int J Tuberc Lung Dis 1999 3 10 847 850 10524579
36. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis, Bull World Health Organ 1982 60 4 555 564 6754120
37. Issues in the management of contacts of patients with active pulmonary tuberculosis. D Menzies, Can J Public Health 1997 88 3 197 201 9260361
38. Global trends in resistance to antituberculosis drugs. MA Espinal A Laszlo L Simonsen F Boulahbal SJ Kim A Reniero S Hoffner HL Rieder N Binkin C Dye R Williams MC Raviglione for the World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance, N Engl J Med 2001 344 1294 1303 10.1056/NEJM200104263441706 11320389
39. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. RM Granich S Balandrano AJ Santaella J Binkin KG Castro A Marquez-Fiol G Anzaldo M Zarate ML Jaimes O Velazquez-Monroy L Salazar C Alvarez-Lucas P Kuri A Flisser J Santos-Preciado C Ruiz-Matus R Tapia-Conyer JW Tappero, Arch Intern Med 2000 160 639 644 10.1001/archinte.160.5.639 10724049
40. Drug-resistant tuberculosis in the Dominican Republic: results of a nationwide survey. MA Espinal J Báez G Soriano V Garcia A Laszlo AL Reingold S Sanchez, Int J Tuberc Lung Dis 1998 2 490 498 9626607
41. The prevalence of tuberculosis and drug resistance among Haitians. AE Pitchenik BW Russell T Cleary I Pejovic C Cole DE Snider Jr, N Engl J Med 1982 307 162 165 6806657
42. Health-care expenditures for tuberculosis in the United States. RE Brown B Miller WR Taylor C Palmer L Bosco RM Nicola J Zelinger K Simpson, Arch Intern Med 1995 155 1595 1600 10.1001/archinte.155.15.1595 7618981
43. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. DE Kopanoff DE Snider Jr GJ Caras, Am Rev Respir Dis 1978 117 991 1001 666111
44. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. LP Ormerod N Horsfield, Tuber Lung Dis 1996 77 37 42 10.1016/S0962-8479(96)90073-8 8733412
45. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. CM Nolan SV Goldberg SE Buskin, JAMA 1999 281 1014 1018 10.1001/jama.281.11.1014 10086436
46. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. D Menzies MJ Dion B Rabinovitch S Mannix P Brassard K Schwartzman, Am J Respir Crit Care Med 2004 170 445 449 10.1164/rccm.200404-478OC 15172892
47. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. N Markowitz NI Hansen TC Wilcosky PC Hopewell J Glassroth PA Kvale BT Mangura D Osmond JM Wallace MJ Rosen LB Reichman, Ann Intern Med 1993 119 185 193 8100692
48. Does size matter? Utility of size of tuberculin reactions for the diagnosis of mycobacterial disease. K Al Zahrani H Al Jahdali D Menzies, Am J Respir Crit Care Med 2000 162 1419 1422 11029355
49. A controlled trial of isoniazid prophylaxis in mental institutions. SH Ferebee FW Mount FJ Murray VT Livesay, Am Rev Respir Dis 1963 88 161 175 14045220
50. Epidemiological basis of tuberculosis eradication. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. O Horwitz E Wilbek PA Erickson, Bull World Health Organ 1969 41 95 113 5309087
51. The incidence of false-positive cultures for Mycobacterium tuberculosis. WJ Burman BL Stone RR Reves ML Wilson Z Yang H el-Hajj, Am J Respir Crit Care Med 1997 155 1 321 326 9001331
52. The chest roentgenogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. R Long B Maycher M Scalcini J Manfreda, Chest 1991 99 123 7 10.1378/chest.99.1.123 1984941
53. Épidémiologie de la tuberculose au Québec de 2000 à 2003. Ministère de la Santé et des Services sociaux du Quebec, Comité Québecois sur la Tuberculose P Rivest Bureau de surveillance épidémiologique, Direction de santé publique de Montréal-Centre, Ministère de la Santé et des Services sociaux, Publications 2006 http://publications.msss.gouv.qc.ca/acrobat/f/ documentation/2006/06-266-01.pdf Accessed January 14, 2008
54. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. K Khan P Muennig M Behta JG Zivin, N Engl J Med 2002 347 1850 1859 10.1056/NEJMsa021099 12466510
55. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. RD Moore CP Chaulk R Griffiths S Cavalcante RE Chaisson, Am J Respir Crit Care Med 1996 154 1013 1019 8887600
56. The cost of tuberculosis: utilization and estimated charges for the diagnosis and treatment of tuberculosis in a public health system. R Wurtz WD White, Int J Tuberc Lung Dis 1999 3 382 387 10331726
57. Causes and costs of hospitalization of tuberculosis patients in the United States. Z Taylor SM Marks NM Rios Burrows SE Weis RL Stricof B Miller, Int J Tuberc Lung Dis 2000 4 931 939 11055760